In #RareCancers, guidelines are vital to bring together scattered expertise. A recent EURACAN survey highlights a high uptake of recommendations from oncologists, potentially leading to improved patients’ survival.
#ESMORareCancers26 #ESMODailyReporter
📌 https://ow.ly/nooJ50YsIQ9
Do you have an impactful research idea?
One that could improve care or advance science?
Apply for the ESMO Leadership & Career Development Award, offering protected research time, leadership & communication training by 3 May 26 .
🔗https://ow.ly/Gicm50YqcbZ
#Oncology #ESMOYOC
Spiderweb 🕸️ is a decentralised clinical trials initiative by the Oncodistinct network. Learn more in this commentary by Nuria Kotecki and Simon Nannini
ascopubs.org/doi/10.1200/...
January 16 & 17, 2026 - Brussels
Two days packed with top expertise, debate, and insights from the past year in breast cancer care.
Institut Jules Bordet & UZ Leuven invite you to this annual double meeting, which has become a fixture
Registration link ✍️👇
accredimix.be/debate-highl...
❄️ 🚲 🧑⚕️ 🏥
Rotterdam citytrip and Union Saint-Gilloise 💛💙 at De Kuip
🚂☀️🚤🏟️
I am a big fan of @fontainesdc.bsky.social and I discovered their partnership with @bfcdublin.bsky.social at Rock Werchter. I immediately loved the club’s vibes. And that third jersey, wow 🤩
I reviewed for @myesmo.bsky.social new data with a potential clinical impact in HR+/HER2- metastatic breast cancer 👇
#ESMOMembers – vote for the leaders who will shape ESMO’s future. Vote now for the Directors of Education, Public Policy & Membership - and the Chair and members of the Nomination Committee.
📽️ Watch the ESMO President’s message
🔗 Vote now: ow.ly/H7UK50VZR0X
Cool simultaneous illustration of my talk at the seminar series organised by Institut Jules Bordet to celebrate Clinical Trials Day
🇩🇪 🚆 🇧🇪 🚌 🏟️ ⚽️💛💙
@hoperugo.bsky.social is discussing the results of the ROSALINE trial, an IIT sponsored by the Institut Jules Bordet that evaluated ROS1 inhibition with neo-adj endocrine therapy in early ILBC #ESMOBreast25 👏🏻 @aftimosp.bsky.social & Soraia Lobo-Martins
Day 2 of #ESMOBreast25 in Munich.
Data on ADCs will be presented during Mini Oral session 1 including results on 2️⃣ novel ADCs targeting B7H4 in HR+/HER2- and TNBC:
emiltatug ledadotin and puxitatug samrotecan
#ESMOAmbassadors @myesmo.bsky.social
Part of the Institut Jules Bordet breast cancer team at #ESMOBreast25
@laubdh.bsky.social
In her Keynote Lecture at #ESMOBreast25, @loisher.bsky.social considers the question of who truly benefits from #immunotherapy in #BreastCancer, noting that success hinges on careful definition of responsive patient subgroups.
Full article in the #ESMODailyReporter
🔗 ow.ly/rtbo50VSyiN
#ESMOBreast25 Award recipient, Gabriel Hortobagyi, describes the long journey that has led to targeted #BreastCancer therapies and explains how patient involvement is central to advancing research.
Read more in the #ESMODailyReporter
🔗 ow.ly/kqju50VSpOE
At #ESMOBreast25, refinements in #LiquidBiopsy use are reviewed, including a defined window for ESR1 mutation detection in metastatic #BreastCancer and use of pre-neoadjuvant treatment #ctDNA levels to predict recurrence.
More in the #ESMODailyReporter
🔗 ow.ly/R93050VSChg
The path forward for immunotherapy biomarkers in breast cancer by @marleenkok.bsky.social
#ESMOBreast25 #ESMOAmbassadors @myesmo.bsky.social
An enthusiast and militant talk by @marleenkok.bsky.social at #ESMOBreast25 on the importance of studying biomarkers for immunotherapy in breast cancer, highlighting the KN522 example
#ESMOAmbassadors @myesmo.bsky.social
#ESMOBreast25 @laubdh.bsky.social from Institut Jules Bordet on the role of immunotherapy in ER+/HER2- early breast cancer #ESMOAmbassadors @myesmo.bsky.social
Sustainable travel 🚆 🌱 🌎 to Munich 🇩🇪 and #ESMOBreast25
#ESMOAmbassadors
@myesmo.bsky.social
@aftimosp.bsky.social @erikahamilton9.bsky.social @marleenkok.bsky.social @ptarantinomd.bsky.social
#ESMOBreast25: Do not miss the latest research findings in #BreastCancer brought to you by the #ESMOAmbassadors & become part of the conversation. #bcsm
🔗 ow.ly/VtAE50VP4Jf
